Go Deep
BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,734 | -3.2 | 3.12 | 0.00 | 24.82 |
| Oct 2026 | 19,734 | -3.1 | 3.12 | 0.00 | 24.77 |
BrightPath Biotherapeutics Co., Ltd. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 11,000.0 | 18,000.0 | 33,000.0 | 0.0 |
| Net Profit | -530,591,000.0 | 112,878,000.0 | -955,092,000.0 | -220,868,000.0 |
| EPS | -3.8 | — | -9.1 | — |
BrightPath Biotherapeutics Co., Ltd. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 84,000.0 | 1,133,000.0 | 72,000.0 | 5,280,000.0 | — |
| Net Profit | -1,304,951,000.0 | -1,151,149,000.0 | -1,168,082,000.0 | -1,485,633,000.0 | — |
| EPS | -11.7 | -14.1 | -18.2 | -24.9 | — |
BrightPath Biotherapeutics Co., Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 2,604,864,000.0 | 1,120,612,000.0 | 1,230,257,000.0 | 1,701,444,000.0 | — |
| Total Liabilities | 236,412,000.0 | 195,626,000.0 | 251,271,000.0 | 133,905,000.0 | — |
| Total Equity | 2,368,452,000.0 | 924,986,000.0 | 978,986,000.0 | 1,567,539,000.0 | — |
Owes vs Owns
BrightPath Biotherapeutics Co., Ltd. owed ¥0.10 for every ¥1 it owned in Jun 2026, up from ¥0.08 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.10× | 0.09× | 0.17× | 0.20× | 0.08× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
BrightPath Biotherapeutics Co., Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 82.8%Other assets 17.2%
How it's funded — Mar 2026
Other liabilities 9.1%Shareholders' equity 90.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,156.2 | 810.5 | 1,057.4 | 1,531.0 |
| Receivables | 0.1 | 1.1 | 0.0 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 448.6 | 309.0 | 172.9 | 170.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 25.0 | 112.5 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 0.0 | 0.0 | 0.0 | 0.1 |
| Other liabilities | 236.4 | 170.6 | 138.8 | 133.8 |
| Shareholders' equity | 2,368.5 | 925.0 | 979.0 | 1,567.5 |
| Net tangible assets | 2,368.5 | 925.0 | 979.0 | 1,567.5 |
BrightPath Biotherapeutics Co., Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -1,365,851,000.0 | -1,250,359,000.0 | -1,156,920,000.0 | -1,204,401,000.0 | — |
| Investing Activities | -1,928,000.0 | -1,370,000.0 | -7,648,000.0 | -1,760,000.0 | — |
| Financing Activities | 2,713,507,000.0 | 1,004,840,000.0 | 690,959,000.0 | 432,104,000.0 | — |